KYMR – kymera therapeutics, inc. (US:NASDAQ)
Stock Stats
News
Kymera Therapeutics (NASDAQ:KYMR) was given a new $80.00 price target on by analysts at Truist Financial Corporation.
Kymera Therapeutics (NASDAQ:KYMR) was given a new $90.00 price target on by analysts at UBS Group AG. They now have a "buy" rating on the stock.
Kymera Therapeutics Announces First Patient Dosed in BROADEN2 Phase 2b Atopic Dermatitis Clinical Trial of KT-621, a First-in-Class, Oral STAT6 Degrader
Kymera Therapeutics to Participate in Upcoming December Investor Conferences
Kymera Therapeutics, Inc. (KYMR) Presents at UBS Global Healthcare Conference 2025 Transcript [Seeking Alpha]
Form SCHEDULE 13G/A Kymera Therapeutics, Filed by: PRICE T ROWE ASSOCIATES INC /MD/
Form SCHEDULE 13G/A Kymera Therapeutics, Filed by: FMR LLC
Form 10-Q Kymera Therapeutics, For: Sep 30
Form 8-K Kymera Therapeutics, For: Nov 04
Form 4 Kymera Therapeutics, For: Oct 29 Filed by: Mainolfi Nello
Top News Gainers
Top News Decliners
Live Event: How Top Hedge Funds Use News To Make Money From The Stock Market & How Ordinary People Are Copying Their Strategies
If you could use the news to make money from the stock market, would you? Join us on our live online event where you’ll discover this simple scientific method that has allowed ordinary people get a huge return from the stock market without excessive risk.